Biocardia Stock Performance
| BCDA Stock | USD 2.66 0.04 1.53% |
On a scale of 0 to 100, Biocardia holds a performance score of 10. The firm shows a Beta (market volatility) of 0.0628, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Biocardia's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biocardia is expected to be smaller as well. Please check Biocardia's maximum drawdown, semi variance, and the relationship between the sortino ratio and potential upside , to make a quick decision on whether Biocardia's price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Biocardia are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady fundamental indicators, Biocardia sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.53 | Five Day Return 3.91 | Year To Date Return 17.7 | Ten Year Return (99.52) | All Time Return (100.00) |
Last Split Factor 1:15 | Dividend Date 2019-06-06 | Last Split Date 2024-05-30 |
1 | Disposition of 3257 shares by Edward Gillis of Biocardia at 2.0 subject to Rule 16b-3 | 12/20/2024 |
2 | Acquisition by Peter Altman of 1000 shares of Biocardia at 2.06 subject to Rule 16b-3 | 12/23/2024 |
3 | Biocardia senior vice president Edward Gillis sells 6,514 in stock - Investing.com | 12/26/2024 |
4 | BioCardia, Inc. Short Interest Down .6 percent in December | 01/17/2025 |
5 | Acquisition by Peter Altman of 500 shares of Biocardia at 2.4 subject to Rule 16b-3 | 01/29/2025 |
6 | Acquisition by Peter Altman of 2 shares of Biocardia at 2.38 subject to Rule 16b-3 | 01/30/2025 |
7 | 12 Health Care Stocks Moving In Mondays Pre-Market Session - Benzinga | 02/03/2025 |
8 | Acquisition by Peter Altman of 600 shares of Biocardia at 2.48 subject to Rule 16b-3 | 02/07/2025 |
9 | Biocardia CEO Peter Altman acquires 1,488 in stock - Investing.com | 02/11/2025 |
10 | Acquisition by Peter Altman of 500 shares of Biocardia at 2.11 subject to Rule 16b-3 | 03/03/2025 |
11 | BioCardia, Inc. Director Simon H. Stertzer Acquires 22,753 Shares | 03/05/2025 |
12 | Reviewing BioCardia Moderna - Defense World | 03/12/2025 |
| Begin Period Cash Flow | 7.4 M | |
| Free Cash Flow | -10 M |
Biocardia |
Biocardia Relative Risk vs. Return Landscape
If you would invest 184.00 in Biocardia on December 19, 2024 and sell it today you would earn a total of 82.00 from holding Biocardia or generate 44.57% return on investment over 90 days. Biocardia is currently generating 0.7813% in daily expected returns and assumes 5.7834% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Biocardia, and 85% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biocardia Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biocardia's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biocardia, and traders can use it to determine the average amount a Biocardia's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1351
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BCDA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.78 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.78 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Biocardia is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biocardia by adding it to a well-diversified portfolio.
Biocardia Fundamentals Growth
Biocardia Stock prices reflect investors' perceptions of the future prospects and financial health of Biocardia, and Biocardia fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biocardia Stock performance.
| Return On Equity | -7.38 | ||||
| Return On Asset | -0.97 | ||||
| Operating Margin | (109.35) % | ||||
| Current Valuation | 8.13 M | ||||
| Shares Outstanding | 4.58 M | ||||
| Price To Earning | (11.00) X | ||||
| Price To Book | 4.36 X | ||||
| Price To Sales | 169.17 X | ||||
| Revenue | 477 K | ||||
| Gross Profit | (4.06 M) | ||||
| EBITDA | (11.56 M) | ||||
| Net Income | (11.57 M) | ||||
| Cash And Equivalents | 8.61 M | ||||
| Cash Per Share | 0.49 X | ||||
| Total Debt | 1.31 M | ||||
| Debt To Equity | 0.26 % | ||||
| Current Ratio | 3.00 X | ||||
| Book Value Per Share | 0.61 X | ||||
| Cash Flow From Operations | (9.97 M) | ||||
| Earnings Per Share | (4.03) X | ||||
| Market Capitalization | 12.01 M | ||||
| Total Asset | 2.99 M | ||||
| Retained Earnings | (152.18 M) | ||||
| Working Capital | (2.15 M) | ||||
| Current Asset | 19.48 M | ||||
| Current Liabilities | 330 K | ||||
About Biocardia Performance
By analyzing Biocardia's fundamental ratios, stakeholders can gain valuable insights into Biocardia's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biocardia has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biocardia has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (7.09) | (7.44) | |
| Return On Tangible Assets | (4.45) | (4.23) | |
| Return On Capital Employed | 16.88 | 17.72 | |
| Return On Assets | (4.45) | (4.23) | |
| Return On Equity | 6.50 | 6.82 |
Things to note about Biocardia performance evaluation
Checking the ongoing alerts about Biocardia for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biocardia help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biocardia is way too risky over 90 days horizon | |
| Biocardia appears to be risky and price may revert if volatility continues | |
| Biocardia has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 477 K. Net Loss for the year was (11.57 M) with loss before overhead, payroll, taxes, and interest of (4.06 M). | |
| Biocardia currently holds about 8.61 M in cash with (9.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49. | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Reviewing BioCardia Moderna - Defense World |
- Analyzing Biocardia's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biocardia's stock is overvalued or undervalued compared to its peers.
- Examining Biocardia's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biocardia's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biocardia's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biocardia's stock. These opinions can provide insight into Biocardia's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biocardia Stock analysis
When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |